Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed LaboratoryCybin Corp. Is A Best In Class Psychedelics Company When Compared To Industry Bellwether Compass PathwaysMindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial AdvisorMind Medicine Inc. Launches First Of Its Kind Clinical Trials Using Synergistic Psychedelic CompoundsNuminus Wellness Is Building A World Class Psychedelic Research OrganizationHAVN Life Sciences Is Off To A Great Start Out Of The GateMydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related AssetsNuminus Announces Closing of Oversubscribed $4.6 Million OfferingRritual™ Announces Suite of Premium Functional Mushroom and Adaptogenic ElixirsCEO Spotlight: Doug Drysdale of Cybin Corp.Aion Therapeutic, Inc. Announces the Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and ChAWAKN Life Sciences Launches Clinical Research Division with Prof. David Nutt & Dr. Ben Sessa Identifying Suitable Apotheca Systems Reveals AI Platform for Psychedelic Assisted PsychotherapyPsychedelics Company Havn Life Announces Commencement of Public Trading on the CSEAion Therapeutic Files Five Patents with the United States Patent and Trademark OfficeCybin Corp Announces Doug Drysdale as Chief Executive OfficerCompass Pathways Is Set To Take Psychedelics Mainstream With An IPO On The NasdaqNuminus Files Restated Financial ReportsMydecine Innovations Group Has Put Together A World Class Organization From A Human Capital PerspectiveMindMed Announces First-Ever Clinical Trial Combining MDMA and LSD

Technical420 Site Search

Returned 47 result(s).

Cybin Corp. Is A Best In Class Psychedelics Company When Compared To Industry Bellwether Compass Pathways

Last week, Compass Pathways (CMPS) commenced trading on the Nasdaq and became the first psychedelic drug company to go public on a major U.S. stock exchange. When Compass filed to go public, the deal generated substantially more interest from investors than expected. As a result, the psychedelic therapy company upsized…

MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor

Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market ("NASDAQ"). As part of this up-listing strategy in the United States, MindMed has submitted an application to list its subordinate…

Mind Medicine Inc. Launches First Of Its Kind Clinical Trials Using Synergistic Psychedelic Compounds

After Champignon Brands was issued a cease trade order from the SEC, the entire psychedelic therapy sector came under pressure and this is a trend that we have been closely following. Although we believe that investors need to conduct significant due diligence and be selective when it comes to the…

Numinus Wellness Is Building A World Class Psychedelic Research Organization

2020 has been a challenging year for the global economy and the COVID pandemic has made an impact on the mental health market. We believe that the pandemic has served as a catalyst for the psychedelic therapy market as healthcare providers and researchers seek new ways to treat debilitating mental…

Numinus Announces Closing of Oversubscribed $4.6 Million Offering

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), is pleased to announce that it has closed its previously announced short form prospectus offering, on a best efforts basis, including the exercise of the agent's option in its entirety in the form of units of the Company (each, a "Unit"). A…

Rritual™ Announces Suite of Premium Functional Mushroom and Adaptogenic Elixirs

 Rritual, the premium brand in the emerging functional mushroom market, announced today that it will launch its suite of premium mushroom and adaptogen enhanced elixirs this fall. Made from a proprietary blend of organic mushrooms and time-tested adaptogenic herbs, Rritual's easy-to-mix elixirs are formulated to blend into your daily wellness…

AWAKN Life Sciences Launches Clinical Research Division with Prof. David Nutt & Dr. Ben Sessa Identifying Suitable Studies Across Europe & North America

AWAKN Life Sciences Inc ("AWAKN"), the European psychedelic assisted psychotherapy company, today announces the launch of its Commercial Clinical Research Division. AWAKN's purpose is broadening access to psychedelic assisted psychotherapy and integrating these services into mainstream mental healthcare in Europe across three business divisions of Clinical Research, Therapeutic Clinics, and…

Compass Pathways Is Set To Take Psychedelics Mainstream With An IPO On The Nasdaq

2020 has been a banner year for the psychedelic sector and we believe that the industry is in the early stages of a major growth cycle. Last week, Compass Pathways announced a major milestone and filed to go public on the Nasdaq Global Market under the symbol CMPS. The leading…

Mind Medicine Inc. Announces Q2 2020 Financial Results

Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has announced its second quarter financial results for the three and six months ended June 30, 2020. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and…

Psychedelic Assisted Therapy Is Becoming A Very Real Alternative Method To Treat Mental Illness

Although the functional mushroom market has been getting a lot of attention, we are most excited about the progress that has been made on the biotech side of the psychedelic industry. There are a few companies in advanced stages of U.S. Food and Drug Administration (FDA) clinical trials and the…

Older Posts »

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link